兴科蓉医药（股票代码：06833）公告显示，该公司将提请股东大会授予股份购回授权，最高可回购不超过已发行股本（不包括库存股份）总数的10%。截至最新日期，公司已发行股份约为20.33亿股，若获股东大会通过，最多可购回约2.03亿股。
根据公告，购回所需资金可来自公司利润或股份溢价账等法定来源，符合香港上市规则等相关法律法规。董事会认为，此举有助提升每股收益及股东回报，不会对营运资金及负债水平造成重大不利影响。公告提及，只有在董事会认为符合公司及股东整体利益时才会进行股份购回。
公司拟于2026年5月15日召开股东周年大会，对此次股份购回授权进行表决。为确定参会资格，公司股东名册自5月12日至15日暂停办理过户。若获得批准，董事会可在合法期间内酌情行使相关权力。公告称，回购计划最终仍需配合市场环境及公司资金状况执行。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.